Coherus BioSciences (CHRS) Misses Q3 EPS by 1c, Misses on Revenue
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.54 -5.52%
EPS Growth %: +23.5%
Financial Fact:
Depreciation and amortization: 14.21M
Today's EPS Names:
CCEL, FEIM, PLG, More
EPS Growth %: +23.5%
Financial Fact:
Depreciation and amortization: 14.21M
Today's EPS Names:
CCEL, FEIM, PLG, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q3 EPS of ($0.33), $0.01 worse than the analyst estimate of ($0.32). Revenue for the quarter came in at $11.6 million versus the consensus estimate of $13.36 million.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- What Delta’s report tells investors in American and United
- Nubank Mexico receives final approval to operate as a full bank
- Financial Select Sector SPDR ETF (XLF) spreader of 20K contracts of July 31 weekly 57 and 59 calls into bank earnings season
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
